21:51 , Jul 27, 2017 |  BC Innovations  |  Strategy

FDA’s regeneration

With $500 million and a bipartisan mandate to innovate regulatory science courtesy of the 21st Century Cures Act, FDA Commissioner Scott Gottlieb has made regenerative medicine a focal point of the agency’s Innovation Initiative, and...
08:00 , Mar 12, 2001 |  BC Week In Review  |  Clinical News

Chondrogel: Pilot

CRIS published in Neurology and Urodynamics that in 32 patients with intrinsic sphincter deficiency resulting in incontinence, a single injection of Chondrogel tissue augmentation product was successful in 26 patients 12 months later. Chondrogel is...
07:00 , Sep 25, 2000 |  BC Week In Review  |  Clinical News

Chondrogel: Completed Phase III trial enrollment

Curis Inc. (CRIS), Cambridge, Mass.   Product: Chondrogel   Business: Biomaterial/Skin/Wound   Therapeutic category: Cell replacement   Target: NA   Description: Autologous cultured cartilage cells   Indication: Treat vesicoureteral reflux   Status: CRIS completed enrollment...
08:00 , Dec 19, 1994 |  BC Week In Review  |  Company News

BioSurface Technology Inc., Genzyme deal

As part of the transaction, GENZ's shareholders also approved the issuance of a new class of common stock (GENZL) that will represent the business of the Tissue Repair Division. The acquisition became effective on Friday;...